Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | JAK2 V617F |
Therapy | Ropeginterferon |
Indication/Tumor Type | myeloproliferative neoplasm |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F | myeloproliferative neoplasm | sensitive | Ropeginterferon | Preclinical - Cell culture | Actionable | In a preclinical study, Ropeginterferon treatment resulted in dose-dependent inhibition of cell proliferation in myeloproliferative neoplasm cell lines harboring JAK2 V617F in culture (PMID: 30287855). | 30287855 |
PubMed Id | Reference Title | Details |
---|---|---|
(30287855) | Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. | Full reference... |